Core Viewpoint - The company has received notification from cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. agreeing to extend the lock-up period until April 30, 2026, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor holds a total of 9.5845 million H-shares, representing approximately 3.43% of the company's total issued H-shares [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]
派格生物医药-B(02565.HK)基石投资者自愿再次延长禁售期